XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a corporate update and reported its financial results for …
Wedbush analyst Liana Moussatos published a new list of upcoming catalysts for a variety emerging pharmaceuticals, including XOMA Corp (NASDAQ:XOMA), Intercept Pharmaceuticals Inc …
Wall Street has an exciting week ahead as earnings season continues to roll on with Tesla Motors Inc (NASDAQ:TSLA), Xoma Corp (NASDAQ:XOMA), Walt Disney …
Recently, various executives have taken part in insider selling activity for the stocks of XOMA Corp (NASDAQ:XOMA), Bank of America Corp (NYSE:BAC), and Palo Alto Networks Inc …
XOMA Corp Stock Starts To Recover XOMA Corp (NASDAQ:XOMA) had an incredibly rough day in the market yesterday. After announcing that a recent Phase 3 …
In a research report released today, Cowen analyst Phil Nadeau downgraded shares of XOMA Corp (NASDAQ:XOMA) from an Outperform to a Market Perform rating, …
Xoma Ltd (NASDAQ:XOMA) shares are dropping 76.56% to $1.
XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the Phase 3 EYEGUARD-B study of gevokizumab in patients …
Investors are patiently awaiting the results of XOMA Corp’s (NASDAQ:XOMA) EYEGUARD B Phase III trial. Shares of the company last closed at $4.
Cowen analyst Phil Nadeau weighed in today with a few insights on XOMA Corp (NASDAQ:XOMA), as data from gevokizumab’s EYEGUARD-B trial is expected over the next couple of weeks. This program …
